Literature DB >> 26462812

Generic and disease-specific estimates of quality of life in macular degeneration: mapping the MacDQoL onto the EQ-5D-3L.

Padraig Dixon1, Helen Dakin2, Sarah Wordsworth2.   

Abstract

PURPOSE: The macular degeneration quality of life (MacDQoL) instrument is a validated condition-specific measure of quality of life in patients with macular degeneration. This paper presents the first mapping algorithm to predict EQ-5D from responses to the MacDQoL instrument.
METHODS: Responses to the MacDQoL and EQ-5D-3L instruments from 482 patients were collected from the IVAN multicentre trial of two alternative drug treatments for neovascular age-related macular degeneration. Regression specifications were estimated using OLS, censored least absolute deviation, Tobit and two-part models. Their predictive performance was assessed using mean squared error. An internal validation sample based on a random selection of 25 % of patients was used to assess the performance of the model estimated on the remaining 75 % of patients.
RESULTS: A two-part model had the best predictive performance on the full sample. The covariates of this model include responses and weighted impact scores for all 23 condition-specific domains of the MacDQoL, and responses to a general MacDQoL quality of life question. The selected models were successful at predicting means and standard deviations of target populations, but prediction is weaker at the upper and lower extremes of the EQ-5D-3L distribution.
CONCLUSION: The mapping algorithms provide a means of predicting EQ-5D-3L index scores from MacDQoL scores, and could facilitate cost-effectiveness analyses when the latter but not the former are available to researchers. Further validation of the performance of the algorithms using external data would provide a means of establishing the robustness of the algorithms.

Entities:  

Keywords:  Age-related macular degeneration; EuroQoL EQ-5D; MacDQoL; Mapping algorithm

Mesh:

Year:  2015        PMID: 26462812     DOI: 10.1007/s11136-015-1145-x

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  24 in total

1.  Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate?

Authors:  Eleanor M Pullenayegum; Jean-Eric Tarride; Feng Xie; Ron Goeree; Hertzel C Gerstein; Daria O'Reilly
Journal:  Value Health       Date:  2010-03-10       Impact factor: 5.725

Review 2.  A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures.

Authors:  John E Brazier; Yaling Yang; Aki Tsuchiya; Donna Louise Rowen
Journal:  Eur J Health Econ       Date:  2009-07-08

Review 3.  The use of condition specific outcome measures in economic appraisal.

Authors:  J Brazier; S Dixon
Journal:  Health Econ       Date:  1995 Jul-Aug       Impact factor: 3.046

4.  Metric properties of the MacDQoL, individualized macular-disease-specific quality of life instrument, and newly identified subscales in French, German, Italian, and American populations.

Authors:  Gilles Berdeaux; Mounir Mesbah; Clare Bradley
Journal:  Value Health       Date:  2011-01       Impact factor: 5.725

Review 5.  Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey.

Authors:  Louise Longworth; Yaling Yang; Tracey Young; Brendan Mulhern; Mónica Hernández Alava; Clara Mukuria; Donna Rowen; Jonathan Tosh; Aki Tsuchiya; Pippa Evans; Anju Devianee Keetharuth; John Brazier
Journal:  Health Technol Assess       Date:  2014-02       Impact factor: 4.014

6.  Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.

Authors:  Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Lucy A Culliford; Barnaby C Reeves
Journal:  Lancet       Date:  2013-07-19       Impact factor: 79.321

7.  Estimating the association between SF-12 responses and EQ-5D utility values by response mapping.

Authors:  Alastair M Gray; Oliver Rivero-Arias; Philip M Clarke
Journal:  Med Decis Making       Date:  2006 Jan-Feb       Impact factor: 2.583

Review 8.  A review of generic preference-based measures of health-related quality of life in visual disorders.

Authors:  Jonathan Tosh; John Brazier; Philippa Evans; Louise Longworth
Journal:  Value Health       Date:  2011-10-01       Impact factor: 5.725

Review 9.  Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database.

Authors:  Helen Dakin
Journal:  Health Qual Life Outcomes       Date:  2013-09-05       Impact factor: 3.186

10.  Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

Authors:  Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Sarah Wordsworth; Barnaby C Reeves
Journal:  Ophthalmology       Date:  2012-05-11       Impact factor: 12.079

View more
  3 in total

1.  "Fibromyalgia and quality of life: mapping the revised fibromyalgia impact questionnaire to the preference-based instruments".

Authors:  Daniel Collado-Mateo; Gang Chen; Miguel A Garcia-Gordillo; Angelo Iezzi; José C Adsuar; Pedro R Olivares; Narcis Gusi
Journal:  Health Qual Life Outcomes       Date:  2017-05-30       Impact factor: 3.186

Review 2.  Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement.

Authors:  Helen Dakin; Lucy Abel; Richéal Burns; Yaling Yang
Journal:  Health Qual Life Outcomes       Date:  2018-02-12       Impact factor: 3.186

3.  Domains of health-related quality of life in age-related macular degeneration: a qualitative study in the Chinese cultural context.

Authors:  Wei Bian; Junli Wan; Graeme Smith; Shiying Li; Mingqiong Tan; Fengjiao Zhou
Journal:  BMJ Open       Date:  2018-04-17       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.